Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22939750 | 0.82 | NR1I2 (0.41) | NR1I2SLC2A1 | |
| SCHEMBL28710729 | 0.77 | NR1I2 (0.44) | NR1I2SLC2A1HTR2ACSNK1E | |
| SCHEMBL23918692 | 0.76 | NR1I2 (0.35) | NR1I2SLC2A1CA2 | |
| SCHEMBL20633856 | 0.76 | NR1I2 (0.50) | NR1I2SLC2A1 | |
| SCHEMBL21346544 | 0.76 | NR1I2 (0.50) | NR1I2SLC2A1 | |
| SCHEMBL23918943 | 0.74 | NR1I2 (0.35) | NR1I2LMNAESR1CSNK1E | |
| SCHEMBL18885441 | 0.74 | NR1I2 (0.49) | NR1I2SLC2A1 | |
| SCHEMBL20615433 | 0.74 | SLC6A3 (0.47) | NR1I2SLC2A1LMNA | |
| SCHEMBL10763616 | 0.74 | UGT2B7 (0.46) | NR1I2LMNA | |
| SCHEMBL10584440 | 0.74 | UGT2B7 (0.46) | NR1I2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315872-A1 | COMPOUNDS AND METHODS FOR EP300 or CBP MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315872-A1 | COMPOUNDS AND METHODS FOR EP300 or CBP MODULATION AND INDICATIONS THEREFOR | EP300, CREBBP, HDAC11 | NR1I2 602/4885SLC2A1 3437/4885HTR2A 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.